National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 2710-2711 [2025-00456]
Download as PDF
<![CDATA[
2710
Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
National Institutes of Health
Dated: January 6, 2025.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institute on Drug Abuse;
Notice of Closed Meetings
ddrumheller on DSK120RN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanistic Studies to Investigate the
Interrelationship Between Sleep and/or
Circadian Rhythms and Substance Use
Disorders.
Date: February 21, 2025.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 827–4471,
ramadanir@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Interplay of Autophagy Regulated Cell Death
and HIV Pathogenesis in Substance Use
Disorders and Research on the NeuroImmune Axis in the Context of HIV and
Substance Use.
Date: February 24, 2025.
Time: 11:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Meysam Yazdankhah,
Ph.D., Scientific Review Officer, Scientific
Review Branch, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 402–
6965, meysam.yazdankhah@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
VerDate Sep<11>2014
18:48 Jan 09, 2025
Jkt 265001
[FR Doc. 2025–00455 Filed 1–10–25; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council for Human Genome Research.
This is a video assisted meeting held
virtually. It is open to the public as
indicated below. Individuals who plan
to view the virtual meeting and need
special assistance or other reasonable
accommodations, should notify the
contact person listed below in advance
of the meeting. The meeting will be
videocast and can be accessed from
https://www.genome.gov/eventcalendar/105th-Meeting-of-NationalAdvisory-Council-for-Human-GenomeResearch.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Human Genome Research.
Date: February 10–11, 2025.
Closed: February 10, 2025, 9:00 a.m. to
10:00 a.m.
Agenda: To review and evaluate grant
applications.
Address: National Human Genome
Research Institute, National Institutes of
Health, 6700B Rockledge Drive, Room 1100,
Bethesda, MD 20892 (Virtual).
Open: February 10, 2025, 10:00 a.m. to 6:00
p.m.
Agenda: Report of Institute Director and
Institute Staff.
Address: National Human Genome
Research Institute, National Institutes of
Health, 6700B Rockledge Drive, Room 1100,
Bethesda, MD 20892 (Virtual).
Closed: February 11, 2025, 11:00 a.m. to
5:00 p.m.
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Address: National Human Genome
Research Institute, National Institutes of
Health, 6700B Rockledge Drive, Room 1100,
Bethesda, MD 20892 (Virtual).
Contact Person: Jennifer L. Troyer, Ph.D.,
Director, Division of Extramural Operations,
National Human Genome Research Institute,
National Institutes of Health, 5635 Fishers
Lane, Suite 4076, Rockville, MD 20852, (301)
480–3565, troyerj@mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
www.genome.gov/council, where an agenda
and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: January 6, 2025.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2025–00469 Filed 1–10–25; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS–
2023–1 Phase II: Adaptation of CRISPR-Based
In Vitro Diagnostics for Rapid Detection of
Select Eukaryotic Pathogens (Topic 119).
Date: February 4, 2025.
Time: 1:00 p.m. to 4:00 p.m.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Rockville, MD
20892 (Video Assisted Meeting).
Agenda: To review and evaluate contract
proposals.
Contact Person: Mario Cerritelli, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
E:\FR\FM\13JAN1.SGM
13JAN1
Federal Register / Vol. 90, No. 7 / Monday, January 13, 2025 / Notices
Diseases, National Institutes of Health, 5601
Fishers Lane, MSC–9823, Rockville, MD
20892, 240–669–5199, cerritem@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 6, 2025.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2025–00456 Filed 1–10–25; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
ddrumheller on DSK120RN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Endocrinology,
Metabolism, Nutrition and Reproductive
Sciences Integrated Review Group; Cellular,
Molecular and Integrative Reproduction
Study Section.
Date: February 5–6, 2025.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Anthony Wing Sang Chan,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 809K,
Bethesda, MD 20892, (301) 496–9392,
chana2@csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
Integrated Review Group; Behavioral
Neuroendocrinology, Neuroimmunology,
Rhythms, and Sleep Study Section.
Date: February 6–7, 2025.
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
VerDate Sep<11>2014
18:48 Jan 09, 2025
Jkt 265001
Meeting Format: Virtual Meeting.
Contact Person: Simon Peter Peron, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Dr., Room 1009K,
Bethesda, MD 20892, (301) 594–6236,
peronsp@csr.nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Science of Implementation in Health and
Healthcare Study Section.
Date: February 6–7, 2025.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Wenjuan Wang, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3154,
Bethesda, MD 20892, (301) 480–8667,
wangw22@mail.nih.gov.
Name of Committee: Biobehavioral and
Behavioral Processes Integrated Review
Group; Biobehavioral Mechanisms of
Emotion, Stress and Health Study Section.
Date: February 6–7, 2025.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: Washington Marriott Georgetown,
1221 22nd Street NW, Washington, DC
20037.
Meeting Format: In Person and Virtual
Meeting.
Contact Person: Brittany L. Mason-Mah,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1000A,
Bethesda, MD 20892, (301) 594–3163,
masonmahbl@mail.nih.gov.
Name of Committee: Social and
Community Influences on Health Integrated
Review Group; Psychosocial Development,
Risk and Prevention Study Section.
Date: February 6–7, 2025.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Anna L Riley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
MSC 7759, Bethesda, MD 20892, 301–435–
2889, rileyann@csr.nih.gov.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics Integrated
Review Group; Maximizing Investigators’
Research Award B Study Section.
Date: February 6–7, 2025.
Time: 9:30 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Sudha Veeraraghavan,
Ph.D., Scientific Review Officer, Center for
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
2711
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4166,
MSC 7846, Bethesda, MD 20892, (301) 827–
5263, sudha.veeraraghavan@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: January 6, 2025.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2025–00468 Filed 1–10–25; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Fiscal Year (FY) 2025 Notice of
Supplemental Funding Opportunity
Substance Abuse and Mental
Health Services Administration
(SAMHSA), Department of Health and
Human Services (HHS).
ACTION: Notice of intent to award
supplemental funding.
AGENCY:
This notice is to inform the
public that Substance Abuse and Mental
Health Services Administration
(SAMHSA) is supporting administrative
supplements in scope of the parent
award for the five (5) eligible grant
recipients funded under the FY 2020
National Consumer and Consumer
Supporter Technical Assistance Centers,
Notice of Funding Opportunity (NOFO)
SM–20–001. The total available funding
is $1,806,000 and each of the five
recipients may receive up to $361,200.
This supplemental funding will extend
the project period by 12 months to
March 30, 2026, as SAMHSA completes
the agency’s efforts to update the
program for the field’s current needs.
Recipients will use the funding to
continue to provide technical assistance
to promote evidence-based care for
adults with serious mental illness
within the scope of their active grant
award.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Damie Jackson-Diop, Public Health
Advisor, Substance Abuse and Mental
Health Services Administration
(SAMHSA), Center for Mental Health
Services (CMHS), 5600 Fishers Lane,
Rockville, MD 20857, telephone (240)
276–0424; email damie.jackson-diop@
samhsa.hhs.gov.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\13JAN1.SGM
13JAN1
]]>Agencies
[Federal Register Volume 90, Number 7 (Monday, January 13, 2025)]
[Notices]
[Pages 2710-2711]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-00456]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS-2023-1 Phase
II: Adaptation of CRISPR-Based In Vitro Diagnostics for Rapid
Detection of Select Eukaryotic Pathogens (Topic 119).
Date: February 4, 2025.
Time: 1:00 p.m. to 4:00 p.m.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Rockville, MD
20892 (Video Assisted Meeting).
Agenda: To review and evaluate contract proposals.
Contact Person: Mario Cerritelli, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious
[[Page 2711]]
Diseases, National Institutes of Health, 5601 Fishers Lane, MSC-
9823, Rockville, MD 20892, 240-669-5199, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: January 6, 2025.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2025-00456 Filed 1-10-25; 8:45 am]
BILLING CODE 4140-01-P
